BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries. Modulus Therapeutics Ginkgo Bioworks Acquires Modulus Therapeutics’ Cell Therapy Assets to Strengthen Next-Gen CAR Designs Modulus Therapeutics is a cell engineering company focused on the design of ne ...